Glembatumumab
Based on 1 publication(s) in Google Scholar
Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. Glembatumumab can be coupled to the microtubule inhibitor monomethyl auristatin E to form glembatumumab vedotin. Glembatumumab vedotin is an antibody-agent coupling (ADC) with antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.69%
- CAS No.: 1020264-78-1
- Molecular Weight:145.56 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
GPNMB
In Vitro
Glembatumumab vedotin (CR011-vcMMAE) (0-2.5 μg/mL, 72 h) shows little growth inhibition in UACC62 melanoma cells without MEK inhibitor pretreatment at a concentration of 0.16 μg/mL, while the same dose of CR011-vcMMAE shows stronger growth inhibition in UACC62 cells pretreated with MEK inhibitor[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | 2011-05 | PHASE1 |
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized GPNMB/Osteoactivin Protein, Human (HEK293, His, HY-P70836) can bind Glembatumumab. The EC50 for this effect is 11.7 ng/mL. -
Flow Cytometry analysis of L929 cells labelling GPNMB (red) with Glembatumumab (anti-GPNMB) (HY-P99205). Cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG2 kappa (HY-P99002). Black-Unlabelled control, cells without incubation with primary antibody.
Product Details
-
CAS No. 1020264-78-1
-
Accession Q14956
-
Synonyms CR011; CDX-011 Antibody
-
Molecular Weight 145.56 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Isotype
Human IgG2 kappa
-
Recommend Isotype Controls
-
Format
-
Human IgG2 kappa
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.69%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. [Abstract]2026 May 14;189(10):2898-2917.e42. PMID: 41916312
Purity & Documentation
References
[1]. Naumovski L, et al. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther. 2010 Apr;12(2):248-57. [Content Brief]
[2]. E Anders Kolb, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014 Oct;61(10):1816-21. [Content Brief]
[3]. Xiaozhong Qian, et al. Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate. Mol Oncol. 2008 Jun;2(1):81-93. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)